Fate Therapeutics (FATE) Misses Q1 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/31/2026

1. INTC
2. AMZN
3. RDDT
4. COIN
5. PINS
6. FSLR
7. SYK
8. DASH
9. GILD
10. SBUX

Go back to Fate Therapeutics (FATE) Misses Q1 EPS by 4c

Fate Therapeutics Reports First Quarter 2016 Financial Results

May 9, 2016 4:01 PM EDT

Phase 1/2 Clinical Trial of ProTmune for Prevention of Acute GvHD and CMV Infection to Begin Enrollment in mid-2016

Adaptive NK Cell Cancer Immunotherapy to be Featured at Innate Killer Summit in mid-May

Immuno-Regulatory CD34+ Cell Therapy Abstract Accepted for Presentation at American Diabetes Association's 76th Scientific Sessions in mid-June

SAN DIEGO, May 09, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders,... More